

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction \geq 40% (LVEF \geq 40%)

Status: Recruiting

Eligibility Criteria

This study is NOT accepting healthy volunteers

Conditions & Interventions

Conditions:

Heart Failure

Keywords:

Heart Failure with Preserved Ejection Fraction,, Mineralocorticoid receptor antagonist (MRA)

More Information

Description: This study is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, event-driven Phase 3 study with independently adjudicated clinical outcome assessments.

Contact(s): Marlene Romero - mlromero@healtheast.org

Principal Investigator: Les Forgosh

Phase: Phase III

IRB Number: STUDY00012258

System ID: NCT04435626

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.